Hal Barron, GlaxoSmithKline R&D chief (GSK via YouTube)

Glax­o­SmithK­line scraps two key mid-stage tri­als for their ICOS drug in the lat­est set­back for the field

An­oth­er ICOS can­cer drug pro­gram is run­ning in­to stormy weath­er, with more bad news for Glax­o­SmithK­line R&D chief Hal Bar­ron.

GSK put out word on …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.